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o A significant number of preclinical and clinical studies pointed out that Multidrug Resistance-
associated Protein (MRP) mediated efflux transport plays an important role in the systemic and
tissue exposure profiles of many drugs and their metabolites and of endogenous compounds, like
bile acids1. A problem associated with the MRP subfamily is that the exact role of the various
isoforms in drug disposition is relatively hard to study, at least partly due to lack of potent and
selective MRP inhibitors2.
o The purpose of this study was to identify selective Mrp3 inhibitors in rat hepatocytes in 
suspension, using the oil spin method3. 
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o Several strong Mrp3 inhibitors were identified using rat hepatocytes in suspension in this optimized 
in vivo relevant in vitro assay.
o Human hepatocytes are currently used with acetaminophen glucuronide as substrate which will 
allow to elucidate cross-species differences for Mrp3/MRP3 inhibition.
o SAR modeling will enable in silico screening of larger libraries and in vitro confirmation for more 
and potent Mrp3/MRP3 inhibitors.
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Figure 2: Graphical presentation of the optimized assay used to screen for Mrp3 inhibitors in rat 
hepatocytes in suspension. The Spectrum Collection (MSDiscovery) and Janssen corporate compound 
collection were used as compound libraries. In total 1494 compounds were screened.
Figure 4: Overview of all compounds registered as positive hit. Based on 3 and 5min intracellular
CDF levels, AUC values were calculated and expressed as % of the AUC obtained for
benzbromarone (100%)(red bar). A 50% cut-off was chosen to distinguish between non-inhibitors
and inhibitors. After screening 1444 compounds of The Spectrum Collection library and a hit rate of
2.5% (36 hits vs 1444 compounds screened) a Naïve Bayesian model in Pipeline Pilot was
constructed. 50 compounds were selected out of Janssen library based on their chemical structures
as being possible Mrp3 inhibitors based on this first model. This second screening resulted in a hit
rate of 30% (15 hits vs 50 compounds screened) (n=2). In total, there was a hit rate of 3.4% (51 hits
vs 1494 compounds screened). (n=2)
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Figure 1: Graphical presentation
of the purpose of this study. The
aim is to identify selective
inhibitors for Mrp3 using a
screening approach in rat
hepatocytes in suspension.
* In suspension, hepatic Mrp2 
activity and expression is very 
low due to internalization 
implying that the present 
approach will elucidate mainly 
Mrp3 inhibitors4.
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Figure 3: Graphical representation of time dependent Mrp3 mediated CDF efflux in rat hepatocytes
in suspension. Based on the results, 3 min and 5 min were selected as time points for screening. The
area under the curve (AUC) of benzbromarone subtracted by the AUC of the control condition
represents 100% inhibition (n=3).
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AUC2
AUC1
AUC1-AUC2 = 100% inhibition
Incubation
CDFDA will react with intracellular 
esterases and CDF, 
benzbromarone or possible Mrp3 
inhibitor with transporter
100% inhibition 
(as depicted in Figure 3)
